Revvity Files 8-K on Financial Results as Q2 Earnings Report Looms
The life sciences technology company disclosed results of operations and financial condition in a regulatory filing ahead of its second-quarter earnings call.
Regulatory Filing Precedes Earnings
Revvity, Inc. (RVTY) filed an 8-K with the Securities and Exchange Commission on August 4, 2026, disclosing results of operations and financial condition. The filing comes as the life sciences technology company prepares to report its second-quarter 2026 results and host an earnings call later the same day, according to MarginX data.
The $13 billion market cap company, which closed at $115.22 in its most recent trading session, is scheduled to hold its Q2 2026 earnings call on August 4, providing investors with detailed financial performance metrics and management commentary.
Recent Corporate Activity
MarginX data shows recent insider transactions at Revvity, including a sale of 85 shares by Anita Gonzales, along with 33 shares withheld for tax purposes. Separately, Pascale Witz received an award of 1,015 shares. These transactions represent routine equity compensation activity typical for public company executives.
Looking Ahead
Beyond today's earnings report, Revvity shareholders have several upcoming dates to note. The company is scheduled to pay a $0.07 cash dividend on October 23, 2026, according to MarginX data. This quarterly distribution continues the company's pattern of returning capital to shareholders.
Investors will also be monitoring the broader macroeconomic environment, with the Federal Reserve's next rate decision and economic projections scheduled for September 16, 2026. Monetary policy decisions could influence sentiment across the life sciences sector, including companies like Revvity that serve pharmaceutical, diagnostic, and research markets.
Company Profile
Revvity operates in the life sciences and diagnostics space, providing instruments, consumables, software, and services to laboratories and research institutions. The United States-based company serves customers across drug discovery, diagnostics, food safety, and environmental markets.
The 8-K filing represents standard regulatory disclosure requirements under SEC rules, providing timely information to investors and the public about material financial developments.
This article was generated by MarginX from public news on 2026-08-04. It is not investment advice.